Search Results - "Naume, B"

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer by Kyte, J A, Røssevold, A, Falk, R S, Naume, B

“…Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC)…”
Get full text

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer by Kyte, J A, Andresen, N K, Russnes, H G, Fretland, S Ø, Falk, R S, Lingjærde, O C, Naume, B

“…Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone…”
Get full text

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging by Fangberget, A., Nilsen, L. B., Hole, K. H., Holmen, M. M., Engebraaten, O., Naume, B., Smith, H.-J., Olsen, D. R., Seierstad, T.

“…Objective To explore the predictive value of MRI parameters and tumour characteristics before neoadjuvant chemotherapy (NAC) and to compare changes in tumour…”
Get full text

Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) by Jerusalem, G., Mariani, G., Ciruelos, E.M., Martin, M., Tjan-Heijnen, V.C.G., Neven, P., Gavila, J.G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., Conte, P.

“…This European phase IIIb, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a patient population similar to BOLERO-2. Post-menopausal…”
Get full text

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome by Bergamaschi, A, Tagliabue, E, Sørlie, T, Naume, B, Triulzi, T, Orlandi, R, Russnes, HG, Nesland, JM, Tammi, R, Auvinen, P, Kosma, V.M, Ménard, S, Børresen-Dale, A.L

“…Prediction of the clinical outcome of breast cancer is multi-faceted and challenging. There is growing evidence that the complexity of the tumour…”
Get full text

Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer by WIEDSWANG, G, BORGEN, E, NAUME, B, KARESEN, R, KVALHEIM, G, NESLAND, J. M, QVIST, H, SCHLICHTING, E, SAUER, T, JANBU, J, HARBITZ, T

“…This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. BM aspirates were…”
Get full text

Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients by Haugen, M.H., Lingjærde, O.C., Garred, Ø., Hedenfalk, I., Loman, N., Mills, G., Borresen-Dale, A.-L., Naume, B., Mælandsmo, G.M., Engebråten, O.

Get full text

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO by Di Cosimo, S., Campbell, C., Azim, H.A., Galli, G., Bregni, G., Curigliano, G., Criscitiello, C., Izquierdo, M., de la Pena, L., Fumagalli, D., Fein, L., Vinholes, J., Ng, W.M.J., Colleoni, M., Ferro, A., Naume, B.J., Patel, A., Huober, J., Piccart-Gebhart, M.J., Baselga, J., de Azambuja, E.

“…To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial…”
Get full text

Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors by Baumbusch, L O, Aarøe, J, Johansen, F E, Hicks, J, Sun, H, Bruhn, L, Gunderson, K, Naume, B, Kristensen, V N, Liestøl, K, Børresen-Dale, A-L, Lingjaerde, O C

“…Microarray Comparative Genomic Hybridization (array CGH) provides a means to examine DNA copy number aberrations. Various platforms, brands and underlying…”
Get full text

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing by Demeulemeester, J, Møller, E.K, Kumar, P, Silje, N, Wedge, D.C, White, K.P, Naume, B, Kristensen, V.N, Van Loo, P, Voet, T

Get full text

Metabolite-guided vs CYP2D6 genotype-guided long-term prediction of outcome in breast cancer patients treated adjuvantly with tamoxifen by Helland, T, Henne, N, Naume, B, Borgen, E, Kristensen, V, Hustad, S, Janssen, E, Lien, E, Mellgren, G, Soiland, H

Get full text

Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome by Synnestvedt, M., Borgen, E., Schlichting, E., Schirmer, C. B., Renolen, A., Giercksky, K. E., Nesland, J. M., Naume, B.

“…Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive…”
Get full text

833 Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer by Silwal-Pandit, L, Russnes, H, Borgen, E, Naume, B, Farnebo, M, Børresen-Dale, A, Langerad, A

Get full text

587 DNA Methylation Profiling Identifies Luminal a Breast Tumors With Poor Survival by Fleischer, T, Jovanovic, J, Edvardsen, H, Alns, G.I.G, Naume, B, Tost, J, Børresen-Dale, A.L, Kristensen, V.N

Get full text

40 Proffered Paper: Dissecting the Genetic Components of Breast Cancer Transcriptomes by Nord, S, Lingjærde, O.C, Nebdal, D, Sun, W, Alnæs, G.I.G, Van Loo, P, Naume, B, Børresen-Dale, A.L, Kristensen, V.N

Get full text

1000 ORAL Luminal A Breast Tumours Divided in Two Clusters by DNA Methylation by Fleischer, T, Jovanovic, J, Edvardsen, H, Alnass, G.I.G, Naume, B, Borresen-Dale, A.L, Tost, J, Kristensen, V.N

Get full text

A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells by Naume, B, Gately, M, Espevik, T

“…IL-12, or cytotoxic lymphocyte maturation factor, is a recently cloned cytokine shown to influence lymphokine-activated killer cells activity in heterogeneous…”
Get full text

Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method by Naume, B., Borgen, E., Tøssvik, S., Pavlak, N., Oates, D., Nesland, J.M.

“…Cell enrichment methods that deal with larger volumes of peripheral blood and BM are needed for increased sensitivity of detection, characterization and…”
Get full text

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells by Borgen, E., Naume, B., Nesland, J.M., Kvalheim, G., Beiske, K., Fodstad, Ø., Diel, I., Solomayer, E.-F., Theocharous, P., Coombes, R.C., Smith, B.M., Wunder, E., Marolleau, J.-P., Garcia, J., Pantel, K.

“…Detection of isolated tumor cells (TC) in BM from carcinoma patients can predict future relapse. Various molecular and immunocytochemical (ICC) methods have…”
Get full text

A European interlaboratory testing of three well‐known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow by Borgen, E., Pantel, K., Schlimok, G., Müller, P., Otte, M., Renolen, A., Ehnle, S., Coith, C., Nesland, J. M., Naume, B.

“…Background: This investigation intended to study the unspecific background to be expected in normal bone marrow (BM), comparing three well recognized protocols…”
Get full text